BMY•benzinga•
Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review
Summary
Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a decision expected by June 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 24, 2025 by benzinga